Marinus Pharma (MRNS) Misses Q4 EPS by 4c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. FIX
8. BE
9. BMY
10. PNFP

Go back to Marinus Pharma (MRNS) Misses Q4 EPS by 4c, Revenues Beat

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results

March 9, 2021 7:00 AM EST

PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5% reduction in seizure frequency for ganaxolone compared to 24.0% for placebo (p=0.17) Interim efficacy and safety evaluation of the CALM Study (open label Phase 2 trial) designed to evaluate the preliminary efficacy and safety of adjunctive ganaxolone treatment in tuberous sclerosis complex (TSC), supports advancing to Phase 3 CALM Study (in TSC) will complete enrollment this week with top line data expected in Q3 2021 Remain on track to submit NDA for use of ganaxolone in CDKL5 deficiency disorder (CDD) in... More